Search
Brinzolamide
go.drugbank.com/drugs/DB01194ApprovedBrinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma. Although the exact pathophysiology of...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesZopiclone
go.drugbank.com/drugs/DB01198ApprovedInvestigationalZopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbitu...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesFomepizole
go.drugbank.com/drugs/DB01213ApprovedVet approvedFomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsAnastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigationalincluding anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: NMDA Receptor Antagonists, Cytochrome P-450 SubstratesQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalSaquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the ...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: P-glycoprotein inhibitors, Dopamine D2 Receptor AntagonistsBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates